Developer docs
API playgroundTry for free, no card

Search company profiles

Genoox

Full company profile

uuid0004ojr

Namestring
Genoox
Legal namestring
Genoox Ltd.
Websiteurl
genoox.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Genoox is a clinical genomics software company that developed Franklin, an AI-powered cloud-based platform for storing, managing, searching, and interpreting genetic variants in clinical settings. Founded in 2012 in Tel Aviv, Israel, the company served clinical genomics laboratories and healthcare providers requiring scalable tools for variant interpretation. The Franklin platform processes VCF files and supports variant search and interpretation across SNP, CNV, and ROH data types, covering both germline and somatic contexts against reference genomes such as hg19. Genoox positioned Franklin as a community-driven platform intended to aggregate real-world evidence (RWE) from clinical genomic and clinical data, creating a data flywheel intended to improve variant interpretation accuracy over time.

The company operated a cloud-based SaaS distribution model with direct digital customer acquisition, primarily marketing through its Franklin platform website and community engagement channels targeted at genomic data professionals. Genoox was venture-backed, raising approximately $20 million across multiple funding rounds from 2014 through 2021, with investors including IN Venture, Glilot Capital Partners, Triventures, Inimiti, Infinity Medical, and UpWest. The company's co-founders were Amir Trabelsi (CEO) and Moshe Einhorn (CTO), with Ohad Arazi appointed Chairman of the Board in June 2021 to support growth and clinical reach. Genoox operated with a small team of 11-50 employees and did not publicly disclose its pricing model or specific revenue figures.

In July 2025, QIAGEN N.V. acquired Genoox for $70 million in cash as a bolt-on transaction to add the Franklin platform to QIAGEN's clinical genomics portfolio. The acquisition provides Genoox with QIAGEN's global clinical genomics distribution network, materially expanding the addressable market for Franklin's AI-powered variant interpretation capabilities. As of the acquisition, Genoox operates as a wholly-owned subsidiary of QIAGEN, with the Franklin platform integrated into QIAGEN's broader clinical genomics product suite to support precision medicine and clinical diagnostic workflows.

Short descriptiontext

Genoox is a clinical genomics software company that developed Franklin, an AI-powered cloud platform for storing, managing, and interpreting genetic variants for clinical laboratories and healthcare providers. Acquired by QIAGEN in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical genomics software, genomic data platform, variant interpretation, AI genomics analysis, precision medicine tools
Industry3 codes
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGANAJ
Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Genomics Software
Social media profiles2 records
Cost components5 values
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Franklin
Description

AI-powered genomic data interpretation platform for clinical variant analysis, now part of QIAGEN's clinical genomics portfolio.

franklin.genoox.com
Core offering1 text field

Genoox provides the Franklin platform, a cloud-based AI-powered software solution for storing, managing, searching, and interpreting clinical genomic data. The platform enables clinical genomics laboratories and healthcare providers to analyze genetic variants (SNP, CNV, ROH) for precision medicine applications. It supports germline and somatic variant interpretation across reference genomes including hg19.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Genoox offers a cloud-based genomic data management and analysis platform centered around the Franklin product. Franklin is an AI-powered clinical genomics platform that enables variant interpretation and genomic data analysis. Following QIAGEN's acquisition of Genoox in July 2025 for $70 million, Franklin was integrated into QIAGEN's clinical genomics portfolio to enhance AI-powered variant interpretation capabilities and expand global reach in precision medicine.

Product and service1 record
1Franklin
CategoryClinical Genomics Software
Description

Franklin is a cloud-based AI-powered genomic data platform for storing, managing, and interpreting genetic variants. It supports variant search using SNP, CNV, and ROH data types with germline analysis capabilities across different reference genomes (hg19), serving clinical genomics laboratories and healthcare providers performing precision medicine applications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven clinical genomics interpretation platform offering variant analysis and clinical reporting workflows; competes directly with Genoox's Franklin in serving clinical laboratories and hospitals needing scalable variant interpretation.

TypeEmerging player
Description

Precision oncology workflow software that combines variant interpretation with clinical decision support; overlaps with Genoox in clinical genomic interpretation but with a narrower oncology focus rather than Genoox's broader germline/somatic scope.

TypeDirect peer
Description

Cloud-based genomics data management and analysis platform used by clinical and research organizations; closely comparable to Genoox's Franklin in providing scalable cloud infrastructure for genomic data storage, search, and interpretation.

TypeDirect peer
Description

Genomics data management and interpretation platform serving clinical research and biobanking customers; comparable to Genoox in offering cloud-based genomic data infrastructure with built-in variant interpretation capabilities.

TypeDirect peer
Description

Clinical genomics interpretation platform with AI-augmented variant analysis for rare disease and precision medicine; directly competes with Genoox in serving clinical laboratories with genomic data interpretation.

TypeBroad incumbent
Description

AI-powered clinical variant interpretation platform now part of Illumina; competes with Genoox in automated clinical variant interpretation and is bundled with Illumina's dominant sequencing platform—creating a powerful incumbent competitor inside QIAGEN's market.

TypeEmerging player
Description

Clinical genomics interpretation and reporting platform serving diagnostic laboratories; comparable to Genoox's Franklin in providing variant interpretation software for clinical workflows with a focus on hereditary disease testing.

8Diploid
TypeEmerging player
Description

AI-driven rare disease diagnosis platform that automates variant interpretation from NGS data; directly comparable to Genoox's Franklin in AI-based clinical interpretation for rare disease and pediatric genomics use cases.

TypeDirect peer
Description

Cloud-based AI platform for genomic and multimodal patient data analysis, used by hospitals and labs globally for variant interpretation; directly comparable to Genoox's Franklin in clinical NGS interpretation and rare disease/oncology workflows.

10PierianDx (now Illumina Connected Insights)
TypeBroad incumbent
Description

Clinical genomics interpretation platform acquired by Illumina; offers overlapping variant interpretation and clinical reporting functionality to Genoox's Franklin, but as part of a larger sequencing ecosystem rather than a standalone specialist.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genoox

Clinical Genomics Softwaregenoox.com

Genoox is a clinical genomics software company that developed Franklin, an AI-powered cloud platform for storing, managing, and interpreting genetic variants for clinical laboratories and healthcare providers. Acquired by QIAGEN in 2025.

What Genoox does

Genoox is a clinical genomics software company that developed Franklin, an AI-powered cloud-based platform for storing, managing, searching, and interpreting genetic variants in clinical settings. Founded in 2012 in Tel Aviv, Israel, the company served clinical genomics laboratories and healthcare providers requiring scalable tools for variant interpretation. The Franklin platform processes VCF files and supports variant search and interpretation across SNP, CNV, and ROH data types, covering both germline and somatic contexts against reference genomes such as hg19. Genoox positioned Franklin as a community-driven platform intended to aggregate real-world evidence (RWE) from clinical genomic and clinical data, creating a data flywheel intended to improve variant interpretation accuracy over time.

The company operated a cloud-based SaaS distribution model with direct digital customer acquisition, primarily marketing through its Franklin platform website and community engagement channels targeted at genomic data professionals. Genoox was venture-backed, raising approximately $20 million across multiple funding rounds from 2014 through 2021, with investors including IN Venture, Glilot Capital Partners, Triventures, Inimiti, Infinity Medical, and UpWest. The company's co-founders were Amir Trabelsi (CEO) and Moshe Einhorn (CTO), with Ohad Arazi appointed Chairman of the Board in June 2021 to support growth and clinical reach. Genoox operated with a small team of 11-50 employees and did not publicly disclose its pricing model or specific revenue figures.

In July 2025, QIAGEN N.V. acquired Genoox for $70 million in cash as a bolt-on transaction to add the Franklin platform to QIAGEN's clinical genomics portfolio. The acquisition provides Genoox with QIAGEN's global clinical genomics distribution network, materially expanding the addressable market for Franklin's AI-powered variant interpretation capabilities. As of the acquisition, Genoox operates as a wholly-owned subsidiary of QIAGEN, with the Franklin platform integrated into QIAGEN's broader clinical genomics product suite to support precision medicine and clinical diagnostic workflows.

Genoox firmographics

Firmographics
Name
Genoox
Legal name
Genoox Ltd.
Website
https://genoox.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
Genoox is a clinical genomics software company that developed Franklin, an AI-powered cloud platform for storing, managing, and interpreting genetic variants for clinical laboratories and healthcare providers. Acquired by QIAGEN in 2025.
Ownership category
akta.pro rank

Genoox industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGANAJ
Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Clinical genomics software
  • Genomic data platform
  • Variant interpretation
  • AI genomics analysis
  • Precision medicine tools

Where Genoox is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Markets served

Genoox business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations

Genoox product offering

Product offering

Core offering

Genoox provides the Franklin platform, a cloud-based AI-powered software solution for storing, managing, searching, and interpreting clinical genomic data. The platform enables clinical genomics laboratories and healthcare providers to analyze genetic variants (SNP, CNV, ROH) for precision medicine applications. It supports germline and somatic variant interpretation across reference genomes including hg19.

Product overview

Genoox offers a cloud-based genomic data management and analysis platform centered around the Franklin product. Franklin is an AI-powered clinical genomics platform that enables variant interpretation and genomic data analysis. Following QIAGEN's acquisition of Genoox in July 2025 for $70 million, Franklin was integrated into QIAGEN's clinical genomics portfolio to enhance AI-powered variant interpretation capabilities and expand global reach in precision medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • Franklin: AI-powered genomic data interpretation platform for clinical variant analysis, now part of QIAGEN's clinical genomics portfolio.

Products and services

  • Franklin Franklin is a cloud-based AI-powered genomic data platform for storing, managing, and interpreting genetic variants. It supports variant search using SNP, CNV, and ROH data types with germline analysis capabilities across different reference genomes (hg19), serving clinical genomics laboratories and healthcare providers performing precision medicine applications.

Companies that use Genoox

Customer profile

Segments1 record

Ideal customer profiles1 record

Genoox technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Genoox partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Genoox competitors and assessment

Company assessment

Direct peers

  • Fabric Genomics: AI-driven clinical genomics interpretation platform offering variant analysis and clinical reporting workflows; competes directly with Genoox's Franklin in serving clinical laboratories and hospitals needing scalable variant interpretation.
  • DNAnexus: Cloud-based genomics data management and analysis platform used by clinical and research organizations; closely comparable to Genoox's Franklin in providing scalable cloud infrastructure for genomic data storage, search, and interpretation.
  • BC Platforms: Genomics data management and interpretation platform serving clinical research and biobanking customers; comparable to Genoox in offering cloud-based genomic data infrastructure with built-in variant interpretation capabilities.
  • Congenica: Clinical genomics interpretation platform with AI-augmented variant analysis for rare disease and precision medicine; directly competes with Genoox in serving clinical laboratories with genomic data interpretation.
  • SOPHiA Genetics: Cloud-based AI platform for genomic and multimodal patient data analysis, used by hospitals and labs globally for variant interpretation; directly comparable to Genoox's Franklin in clinical NGS interpretation and rare disease/oncology workflows.

Emerging players

  • GenomOncology: Precision oncology workflow software that combines variant interpretation with clinical decision support; overlaps with Genoox in clinical genomic interpretation but with a narrower oncology focus rather than Genoox's broader germline/somatic scope.
  • Aranscia: Clinical genomics interpretation and reporting platform serving diagnostic laboratories; comparable to Genoox's Franklin in providing variant interpretation software for clinical workflows with a focus on hereditary disease testing.
  • Diploid: AI-driven rare disease diagnosis platform that automates variant interpretation from NGS data; directly comparable to Genoox's Franklin in AI-based clinical interpretation for rare disease and pediatric genomics use cases.

Broad incumbents

  • Emedgene (Illumina): AI-powered clinical variant interpretation platform now part of Illumina; competes with Genoox in automated clinical variant interpretation and is bundled with Illumina's dominant sequencing platform—creating a powerful incumbent competitor inside QIAGEN's market.
  • PierianDx (now Illumina Connected Insights): Clinical genomics interpretation platform acquired by Illumina; offers overlapping variant interpretation and clinical reporting functionality to Genoox's Franklin, but as part of a larger sequencing ecosystem rather than a standalone specialist.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Genoox social profiles

Digital presence

Genoox financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genoox leadership team

Management profile

Number of profiles

Profiles3 records

Genoox funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genoox M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoox

What does Genoox do?

Genoox provides the Franklin platform, a cloud-based AI-powered software solution for storing, managing, searching, and interpreting clinical genomic data. The platform enables clinical genomics laboratories and healthcare providers to analyze genetic variants (SNP, CNV, ROH) for precision medicine applications. It supports germline and somatic variant interpretation across reference genomes including hg19.

Is Genoox a public or private company?

Genoox is a private company. It is classified as corporate owned and is currently acquired.

When was Genoox founded?

Genoox was founded in 2012. It employs 51 to 100 people.

Where is Genoox based?

Genoox is headquartered in Palo Alto, United States, in the North America region.

Who are Genoox's main competitors?

Direct peers on record are Fabric Genomics, DNAnexus, BC Platforms, Congenica and SOPHiA Genetics. Emerging players are GenomOncology, Aranscia and Diploid. Broad incumbents are Emedgene (Illumina) and PierianDx (now Illumina Connected Insights).

Does Genoox have an API?

No public API is recorded for Genoox.

What industry is Genoox in?

Genoox's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBiobanking Market worth $12.38 billion by 2031 - Exclusive Report by MarketsandMarkets™The biobanking market is projected to grow from $8.09 billion in 2026 to $12.38 billion by 2031, a CAGR of 8.9%. North America held the largest regional share at ~43.3% in 2025, and the sample collection & storage segment led with ~65.2% of the product market. Growth is driven by cell and gene therapy demand and AI-enabled sample-to-data platforms.PR NewswireBiobanking Market worth $12.38 billion by 2031 - Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the biobanking market to grow from $8.09 billion in 2026 to $12.38 billion by 2031, an 8.9% CAGR. North America held the largest regional share at ~43.3% in 2025, and the sample collection & storage segment led with ~65.2% of the products market. Growth is driven by cell and gene therapy demand and AI-enabled sample-to-data platforms.Grand View ResearchHigh-throughput Genomic Screening For Preventive Healthcare Market Report, 2026-2033The global high-throughput genomic screening market for preventive healthcare is projected to grow from USD 846.1 million in 2025 to USD 2,169.7 million by 2033, driven by the shift toward personalized prevention and technological advancements in next-generation sequencing. Key industry developments include strategic acquisitions such as QIAGEN's purchase of Genoox and Swiss Rockets AG's acquisition of Complete Genomics to enhance AI-powered analysis capabilities. Market expansion is further supported by increasing consumer demand for direct-to-consumer insights and the integration of genomic testing into national healthcare systems like the UK's NHS.openPR.comLeading Firms Fueling Growth and Innovation in the Bioinformatics Services MarketThe bioinformatics services market is projected to reach $10.55 billion by 2030 with a 17.5% compound annual growth rate, driven by precision medicine adoption, omics research, and AI integration. In July 2025, QIAGEN N.V. acquired Genoox Ltd. to enhance its clinical genomics portfolio with AI-powered variant interpretation technology. Additionally, in July 2023, FOXO Technologies Inc. launched its Bioinformatics Services platform to accelerate epigenetic data analysis.Grand View ResearchU.S. Forensic Genomics Market To Reach $941.0Mn By 2033The U.S. forensic genomics market is projected to reach $941.0 million by 2033, growing at a 15.65% CAGR from 2025 to 2030. Kits & consumables led the product segment with a 67.19% revenue share in 2024, and criminal testing captured 66.15% of the application market. The report also notes QIAGEN's $70 million acquisition of Genoox in May 2025.Financial TimesQIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software – Company AnnouncementQIAGEN signed a definitive agreement to acquire Genoox, an AI-powered clinical genomics software provider, for $70 million in cash plus up to $10 million in milestones. The acquisition adds Franklin, a cloud platform used by over 4,000 healthcare organizations, to QIAGEN's Digital Insights portfolio. The deal is expected to generate about $5 million in sales in 2025.Business Wire BlogQIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered softwareQIAGEN agreed to acquire Genoox, an AI-powered clinical genomics software provider, for $70 million in cash plus up to $10 million in milestones. The deal adds Franklin, a cloud platform used by over 4,000 healthcare organizations, to QIAGEN's Digital Insights portfolio. The acquisition is expected to generate about $5 million in sales in 2025.Investing.comQIAGEN acquires Genoox to enhance genetic data analysis By Investing.comQIAGEN completed its acquisition of Genoox for $70 million plus up to $10 million in milestone payments. The deal adds Franklin, an AI platform for genomic data interpretation, to QIAGEN's Digital Insights suite, with integration expected to contribute about $5 million in sales in 2025.FinancialContent Business PageQIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered softwareQIAGEN agreed to acquire Genoox, an AI-powered clinical genomics software provider, for $70 million in cash plus up to $10 million in milestones. The deal adds Franklin, a cloud platform used by over 4,000 healthcare organizations, to QIAGEN's Digital Insights portfolio. The acquisition is expected to generate about $5 million in sales in 2025.QiagenQIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered softwareQIAGEN has signed a definitive agreement to acquire Genoox, a provider of AI-powered clinical genomics software, for $70 million in cash with potential additional milestone payments. This acquisition adds Genoox's Franklin platform to QIAGEN Digital Insights, aiming to strengthen its leadership in genetic interpretation and expand services for small and mid-sized labs globally. The transaction is expected to generate approximately $5 million in sales for QIAGEN in 2025.